February 21, 2017 / 1:45 PM / 6 months ago

BRIEF-Medicines Co says FDA accepts NDA filing for intravenous antibiotic carbavance

Feb 21 (Reuters) - Medicines Co

* The Medicines Company announces FDA filing acceptance of new drug application for intravenous antibiotic carbavance(meropenem-vaborbactam)

* Medicines Co - FDA does not currently plan to hold an advisory committee meeting to discuss application

* Medicines co says tango 2 trial is ongoing and company expects results to be available before end of Q3 of 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below